- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04685057
Probiotic Treatment for Prader-Willi Syndrome
Probiotics as a Long-term Treatment Strategy for Prader-Willi Syndrome
A whole new research area studying the function of intestinal microorganisms, also known as gut microbiota, has emerged during the last decade. As a result, dietary supplementation with specific bacteria (or probiotics) holds great promise as a therapeutic strategy for a wide range of diseases, from obesity to anxiety and depression, all of which are major characteristics of Prader-Willi syndrome (PWS).
The main objective of the current proposal is to determine the effects of Bifidobacterium animalis subsp. lactis (strain BPL1) supplementation in children and young adults with PWS. Specifically, participants will receive placebo or BPL1 for 6 months, and then this phase will be followed by a 6-month extension period in which all participants will receive BPL1. This study will allow us to 1) determine the effects on fat mass and glucose metabolism; and 2) explore the effects on mental health symptoms by studying potential structural changes in the brain by magnetic resonance imaging (MRI) as well as using a number of psychiatric questionnaires.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08950
- Hospital Sant Joan de Deu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with Prader-Willi Syndrome with genetic confirmation
- On a stable diet and medication regimen for at least the last two months before enrollment
Exclusion Criteria:
- Current enrollment in or discontinuation within the last 30 days from a clinical trial
- Patients with bariatric surgery in the last two years
- Patients with Type 2 Diabetes on insulin therapy
- Presence of other medical problems that would preclude study participation
- Unsuitable for inclusion in the study in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
This arm will receive placebo for 6 months then probiotic for 6 more months.
|
Intervention with a daily dose of placebo for 6 months
Intervention with a daily dose of probiotic for 6 months
|
Experimental: Probiotic
This arm will receive probiotic for 6 months then will keep receiving probiotic for 6 more months.
|
Intervention with a daily dose of probiotic for 6 months
Intervention with a daily dose of probiotic for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in percent body fat content
Time Frame: 6 months
|
Body fat content will be measured by dual energy x-ray absorptiometry (DXA)
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BMI and BMI z-score
Time Frame: Baseline, 6, and 12 months
|
Weight and height will be combined to calculate changes in BMI and BMI z scores from all subjects will be assessed
|
Baseline, 6, and 12 months
|
Change in height (cm)
Time Frame: Baseline, 6, and 12 months
|
Changes in height from subjects that have not yet reached final height will be measured.
|
Baseline, 6, and 12 months
|
Change in insulin sensitivity
Time Frame: Baseline, 6, and 12 months
|
Fasting blood glucose and insulin concentrations will be combined to calculate HOMA-IR (Homeostatic Model Assessment for Insulin Resistance).
|
Baseline, 6, and 12 months
|
Change in lipid profile (triglyceride, cholesterol)
Time Frame: Baseline, 6, and 12 months
|
Blood test after overnight fasting
|
Baseline, 6, and 12 months
|
Change in hyperphagia
Time Frame: Baseline, 6, and 12 months
|
Measured by the validated Hyperphagia Questionnaire for Clinical Trials (HQ-CT), specific for subjects with Prader-Willi syndrome (scale 0-36, higher values indicate higher degree of hiperphagia).
Parental or caregiver reported.
|
Baseline, 6, and 12 months
|
Change in Aberrant Behavior Checklist (ABC) score
Time Frame: Baseline, 6, and 12 months
|
The Aberrant Behavior Checklist (ABC) is a 58-item questionnaire.
It consists of five subscales: hyperactivity (0-48), lethargy (0-48), stereotypical behavior (0-21), irritability (0-45), and inappropriate speech (0-12).
Higher scores indicate worse outcome.
Parental or caregiver reported.
|
Baseline, 6, and 12 months
|
Change in Repetitive Behavior Scale (RBS) score
Time Frame: Baseline, 6, and 12 months
|
The Repetitive Behavior Scale (RBS) measures repetitive behaviors that are related to autism.
It consists of 43-items grouped in two different scores: higher-order (ritualistic, sameness, compulsive and restricted subscales; score 0-87) and lower-order (stereotypy and self-injury; score 0-42) repetitive behaviors.
Higher scores indicate worse outcome.
Parental or caregiver reported.
|
Baseline, 6, and 12 months
|
Change in Social Responsiveness Scale (SRS) score
Time Frame: Baseline, 6, and 12 months
|
Measured by the validated Social Responsiveness Scale (SRS-2) which assesses autism-related symptoms focusing on social function.
Higher values indicate worse outcome.
A total score of 76 or higher is considered severe; a score between 66 and 75 is considered moderate; a score between 60 and 65 is considered mild; a score of 59 or lower is considered within normal limits.
Parental or caregiver reported.
|
Baseline, 6, and 12 months
|
Change in Clinical Global Impression (GCI score) score
Time Frame: Baseline, 6, and 12 months
|
Measured by the validated Clinical Global Impression Scale (CGI, scale 0-14, higher values indicate worse outcome).
This toll will be completed by the clinician.
|
Baseline, 6, and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in intestinal microbiota composition
Time Frame: Baseline, 6, and 12 months
|
DNA isolated from fecal samples will be analyzed by sequencing the hypervariable region of the bacterial 16S gene.
|
Baseline, 6, and 12 months
|
Change in plasma metabolome
Time Frame: Baseline, 6, and 12 months
|
Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples
|
Baseline, 6, and 12 months
|
Changes in brain structural anatomy
Time Frame: Baseline, 6, and 12 months
|
Subjects older that 12 years of age will undergo brain magnetic resonance imaging (MRI).
Changes in orbitofrontal cortex, amygdala, hypothalamus, and total gray matter volume will be evaluated.
|
Baseline, 6, and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marta Ramon-Krauel, Hospital Sant Joan de Deu
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Overnutrition
- Nutrition Disorders
- Genetic Diseases, Inborn
- Intellectual Disability
- Abnormalities, Multiple
- Chromosome Disorders
- Obesity
- Syndrome
- Prader-Willi Syndrome
Other Study ID Numbers
- PIC-194-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prader-Willi Syndrome
-
University Hospital, ToulouseCompletedPrader Willi SyndromeFrance
-
University of FloridaNational Institutes of Health (NIH)Completed
-
Samsung Medical CenterCompletedObesity | Prader Willi Syndrome
-
Duke UniversityCanadian Institutes of Health Research (CIHR); National Institutes of Health... and other collaboratorsCompleted
-
California State University, FullertonUniversity of FloridaUnknownFamily-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study (APAH)Childhood Obesity | Prader Willi SyndromeUnited States
-
SanionaCompletedConfirmed Genetic Diagnosis of Prader-Willi SyndromeCzechia, Hungary
-
Weill Medical College of Cornell UniversityNational Institutes of Health (NIH); PWSAUSATerminatedPrader-willi SyndromeUnited States
-
Ferring PharmaceuticalsCompletedHyperphagia in Prader-Willi SyndromeUnited States
-
University of FloridaFoundation for Prader-Willi ResearchCompleted
-
ACADIA Pharmaceuticals Inc.RecruitingHyperphagia in Prader-Willi SyndromeUnited States, Canada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States